Latest News

The sildenafil oral film is expected to be commercially available in the US in March 2026.

URO-1’s FDA-cleared SUREcore and coreCARE prostate biopsy devices have been adopted at multiple Novant Health hospitals as part of a systemwide value analysis.

The conversation explores evolving strategies that have further lowered infection risk, including no-touch principles, chlorhexidine skin preparation, antibiotic and customizable implant coatings, and growing interest in antiseptic-based solutions rather than antibiotics alone.

At 24 months, apalutamide demonstrated a statistically significant improvement in OS vs darolutamide without concurrent docetaxel.

Amy Pearlman, MD, sits down with Katherine A. Amin, MD, to discuss the evolving landscape of female pelvic medicine, overactive bladder management, and fellowship training.

The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

The conversation highlights the steady pace of innovation in urogynecology.

Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.

In this episode, Amy Pearlman, MD, speaks with Phillip M. Pierorazio, MD, about integrating mindfulness and wellness into a demanding surgical career and the evolving complexities of modern prostate cancer care.

The combination was tolerable and demonstrated promising early efficacy as a 3rd-line option for patients with mCRPC.